In one paragraphArticle in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
25 authors.
Chin-An YangEmory University, Nutrition and Health Sciences Program, Laney Graduate School, Atlanta, GA, USA.ORCID 0000-0003-0232-794X Young-Mi GoEmory University, School of Medicine, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Atlanta, GA, USA.ORCID 0009-0005-0211-177X Dean P JonesEmory University, School of Medicine, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Atlanta, GA, USA.ORCID 0000-0002-2090-0677 Brahmchetna BediEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0003-0504-1277 Qian YangEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0002-8102-288X C Christina MehtaEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0001-6854-7983 Igho OfotokunEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0003-2735-1903 Anandi N ShethEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0002-6305-2727 Mohammed K AliEmory University, Rollins School of Public Health, Atlanta, GA, USA.
Sami TeenyEmory University, School of Medicine, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Atlanta, GA, USA.
Maria L AlcaideUniversity of Miami Health, Miller School of Medicine, Department of Medicine, Division of Infectious Diseases, Miami, FL, USA.ORCID 0000-0003-4648-0145 Frank J PalellaNorthwestern University Feinberg School of Medicine, Department of Medicine, Division of Infectious Diseases, Chicago, IL, USA.ORCID 0000-0002-2277-6841 Elizabeth F TopperJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jennifer CocohobaUniversity of California San Francisco School of Pharmacy, Department of Clinical Pharmacy, San Francisco, CA, USA.
Seble G KassayeGeorgetown University, Department of Medicine, Washington, DC, USA.
Michael AugenbraunState University of New York Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, USA.ORCID 0000-0002-8277-2850 Thomas R ZieglerEmory University, Nutrition and Health Sciences Program, Laney Graduate School, Atlanta, GA, USA.
Jessica A AlvarezEmory University, Nutrition and Health Sciences Program, Laney Graduate School, Atlanta, GA, USA.
Cecile D LahiriEmory University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.ORCID 0000-0002-5605-8266 Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MVirology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MQAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7MMaternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8MSF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3MSex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8MUniversity of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8MClinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7MSex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2MNCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS K24 HL176324NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI124414NIDDK NIH HHS R01 DK125246NIMH NIH HHS P30 MH116867
6 · The paper itselfAbstract
backgroundIntegrase strand-transfer inhibitors (INSTIs) are associated with weight gain in people with HIV (PWH), particularly in women with HIV (WWH), but underlying mechanisms remain unclear. We used longitudinal untargeted metabolomics to identify metabolic signatures of INSTI-related weight gain in WWH.
methodsWe analyzed serum from 192 participants in the Women's Interagency HIV Study: 38 virologically suppressed WWH who initiated INSTIs (INSTI group), 88 virologically suppressed WWH who remained on their original antiretroviral therapy (non-INSTI group), and 66 women without HIV (WWoH). Samples were collected at baseline (6-12 months before INSTI initiation), 1-6 months post-initiation, and 1-2 years post-initiation, with matched visits for controls. High-resolution metabolomics was performed by liquid chromatography-mass spectrometry. Within each group, linear mixed-effects models adjusted for baseline age and BMI compared longitudinal metabolite changes between weight gainers and maintainers, and significant features were analyzed by Mummichog v2.0 pathway enrichment.
resultsMean age was 45.7 ± 8.9 years and mean BMI 32.4 ± 8.3 kg/m2, with no differences across groups; within each group, gainers and maintainers were demographically comparable (p > 0.05). In the INSTI group, metabolites differentiating gainers from maintainers were enriched in 16 pathways across timepoints, predominantly lipid-related (56%), including the polyunsaturated fatty acid (PUFA) pathways linoleic acid and arachidonic acid metabolism. In the non-INSTI and WWoH groups, differentiating metabolites spanned a broader range of pathways, including amino acid metabolism.
conclusionsWeight gain among INSTI-treated WWH is characterized by a distinct, lipid- and PUFA-dominated metabolic profile, providing mechanistic insight that may inform therapeutic strategies.
Indexed as
Antiretroviral therapyarachidonic acidlinoleic acidlipid metabolismoxylipinspolyunsaturated fatty acids
Identifiers
PMID42366600
PMCPMC13629715
What OpenQuestion holds
Textmetadata
Read underepoch 390